Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2024 Oct 26

PMID 39458907

Authors

Giuseppe Cicala

Giulia Russo

Vincenza Santoro

Tindara Franchina

Nicola Silvestris

Mariacarmela Santarpia

Edoardo Spina

Maria Antonietta Barbieri

Affiliations

Soon will be listed here.

Abstract

: Monoclonal antibodies (mAbs) have revolutionized multiple myeloma (MM) treatment. However, post-marketing data on their neuropsychiatric safety are limited. This study aimed to evaluate neuropsychiatric adverse events (AEs) related to mAbs used for MM through a retrospective pharmacovigilance analysis using the Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS) database. : Individual case safety reports (ICSRs) from 2015 to 2023 with at least one neuropsychiatric AE and one of the MM-approved mAbs as the suspected drug (i.e., daratumumab, elotuzumab, isatuximab, belantamab mafodotin, teclistamab, elranatamab, and talquentamab) were analyzed using descriptive and disproportionality approaches. : Unknown signals of disproportionate reporting (SDR) included the following: cerebral infarction for daratumumab ( = 45; reporting odds ratio (ROR) = 2.39, 95% confidence interval (CI) = 1.79-3.21; information component (IC) = 1.54, IC-IC = 1.05-1.9), elotuzumab (25; 7.61, 5.13-11.28; 3.03, 2.37-3.51), and isatuximab (10; 2.56, 1.38-4.76; 1.67, 0.59-2.4); mental status changes for daratumumab (40; 2.66, 1.95-3.63; 1.67, 1.14-2.04) and belantamab mafodotin (10; 4.23, 2.28-7.88; 2.3, 1.22-3.03); an altered state of consciousness for daratumumab (32; 1.97, 1.39-2.78; 1.32, 0.73-1.74) and belantamab mafodotin (6; 2.35, 1.05-5.23; 1.6, 0.19-2.52); Guillain-Barre syndrome (GBS) for daratumumab (23; 6.42, 4.26-9.69; 2.81, 2.11-3.3), isatuximab (8; 10.72, 5.35-21.48; 3.57, 2.35-4.37), and elotuzumab (3; 4.74, 1.53-14.7; 2.59, 0.52-3.8); and orthostatic intolerance for daratumumab (10; 12.54, 6.71-23.43; 3.75, 2.67-4.48) and elotuzumab (4; 28.31, 10.58-75.73; 5, 3.24-6.08). : Our analysis highlighted several previously unacknowledged SDRs for MM-approved mAbs. Given the complex and not entirely understood etiology of some neuropsychiatric AEs, including GBS, further investigations are necessary.

References

Wudhikarn K, Wills B, Lesokhin A . Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action. Best Pract Res Clin Haematol. 2020; 33(1):101143. PMC: 7060936. DOI: 10.1016/j.beha.2020.101143. View

Lin Y, Kao T, Chen W . Relationship between peripheral neuropathy and cognitive performance in the elderly population. Medicine (Baltimore). 2021; 100(20):e26071. PMC: 8137106. DOI: 10.1097/MD.0000000000026071. View

Siegel D, Martin T, Wang M, Vij R, Jakubowiak A, Lonial S . A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012; 120(14):2817-25. PMC: 4123387. DOI: 10.1182/blood-2012-05-425934. View

Celi L, Moseley E, Moses C, Ryan P, Somai M, Stone D . From Pharmacovigilance to Clinical Care Optimization. Big Data. 2015; 2(3):134-141. PMC: 4630790. DOI: 10.1089/big.2014.0008. View

Pozzi S, Bari A, Pecherstorfer M, Vallet S . Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma. Cancers (Basel). 2021; 13(19). PMC: 8508369. DOI: 10.3390/cancers13194978. View

Raschi E, Fusaroli M, Giunchi V, Repaci A, Pelusi C, Mollica V . Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System. Cancers (Basel). 2022; 14(19). PMC: 9559636. DOI: 10.3390/cancers14194610. View

Rahman S, Veeraballi S, Chan K, Shaaban H . Bleeding Diathesis in Multiple Myeloma: A Rare Presentation of a Dreadful Emergency With Management Nightmare. Cureus. 2021; 13(3):e13990. PMC: 8053230. DOI: 10.7759/cureus.13990. View

Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau J, Mohty M . Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica. 2010; 95(2):311-9. PMC: 2817035. DOI: 10.3324/haematol.2009.012674. View

Richardson P, Laubach J, Schlossman R, Mitsiades C, Anderson K . Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. J Natl Compr Canc Netw. 2010; 8 Suppl 1:S4-S12. DOI: 10.6004/jnccn.2010.0115. View

10.

Zivkovic S, Lacomis D, Lentzsch S . Paraproteinemic neuropathy. Leuk Lymphoma. 2009; 50(9):1422-33. DOI: 10.1080/10428190903111922. View

11.

Barbieri M, Sorbara E, Cicala G, Santoro V, Cutroneo P, Franchina T . Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database. Drugs Real World Outcomes. 2021; 9(1):91-107. PMC: 8844323. DOI: 10.1007/s40801-021-00278-z. View

12.

Smets I, Titulaer M . Antibody Therapies in Autoimmune Encephalitis. Neurotherapeutics. 2022; 19(3):823-831. PMC: 8775146. DOI: 10.1007/s13311-021-01178-4. View

13.

Markham A . Belantamab Mafodotin: First Approval. Drugs. 2020; 80(15):1607-1613. DOI: 10.1007/s40265-020-01404-x. View

14.

Barbieri M, Russo G, Sorbara E, Cicala G, Franchina T, Santarpia M . Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System. Front Oncol. 2023; 13:1268672. PMC: 10646181. DOI: 10.3389/fonc.2023.1268672. View

15.

Montastruc J, Sommet A, Bagheri H, Lapeyre-Mestre M . Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011; 72(6):905-8. PMC: 3244636. DOI: 10.1111/j.1365-2125.2011.04037.x. View

16.

Cicala G, de Filippis R, Barbieri M, Cutroneo P, De Fazio P, Schoretsanitis G . Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database. Front Psychiatry. 2023; 14:1130636. PMC: 10116827. DOI: 10.3389/fpsyt.2023.1130636. View

17.

Moreau P, Garfall A, van de Donk N, Nahi H, San-Miguel J, Oriol A . Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022; 387(6):495-505. PMC: 10587778. DOI: 10.1056/NEJMoa2203478. View

18.

Richardson P, Siegel D, Vij R, Hofmeister C, Baz R, Jagannath S . Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014; 123(12):1826-32. PMC: 3962162. DOI: 10.1182/blood-2013-11-538835. View

19.

Muscogiuri G, Verde L, Vetrani C, Barrea L, Savastano S, Colao A . Obesity: a gender-view. J Endocrinol Invest. 2023; 47(2):299-306. PMC: 10859324. DOI: 10.1007/s40618-023-02196-z. View

20.

Bird S, Cairns D, Menzies T, Boyd K, Davies F, Cook G . Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. Clin Lymphoma Myeloma Leuk. 2021; 21(10):667-675. PMC: 8528179. DOI: 10.1016/j.clml.2021.04.013. View